Y Soga1, O Iida, D Kawasaki, K Hirano, T Yamaoka, K Suzuki. 1. Kokura Memorial Hospital, Department of Cardiology, 3-2-1 Asano, Kokurakita-ku, Kitakyushu 802-0001, Japan. soga@circulation.jp
Abstract
OBJECTIVE: To investigate whether cilostazol reduces restenosis and revascularization after infrapopliteal angioplasty. DESIGN: This study was a retrospective analysis of a multicenter prospective registry. MATERIALS AND METHODS: Between February and April 2011, 63 patients (68 limbs, 101 lesions) with critical limb ischemia (CLI) were enrolled. Of these, 32 were cilostazol treated and 31 were the non-cilostazol-treated group. Outcome measures were binary restenosis by angiogram, reocclusion, target lesion revascularization (TLR), limb salvage rate and complete wound healing at 3 months. RESULT: Procedural success was obtained in all patients. The backgrounds and lesion characteristics of patients with isolated tibial artery disease and CLI did not differ significantly between the two groups. In a lesion-based analysis, binary restenosis and reocclusion were significantly lower in the cilostazol group than in the non-cilostazol group (56.8% vs. 86.0%; p = 0.015, 20.5% vs. 43.6%; p = 0.015, respectively). The TLR was also significantly lower in the cilostazol group (27.5% vs. 52.8%, p = 0.014). After adjustment for covariables, cilostazol was found to be associated with reduced angiographic restenosis, reocclusion and TLR rates in CLI patients at 3 months after infrapopliteal angioplasty. However, it remained unclear whether cilostazol was also associated with improved clinical outcomes. CONCLUSION: Cilostazol may be associated with reduced restenosis, reocclusion and clinically driven TLR at 3 months after infrapopliteal angioplasty.
OBJECTIVE: To investigate whether cilostazol reduces restenosis and revascularization after infrapopliteal angioplasty. DESIGN: This study was a retrospective analysis of a multicenter prospective registry. MATERIALS AND METHODS: Between February and April 2011, 63 patients (68 limbs, 101 lesions) with critical limb ischemia (CLI) were enrolled. Of these, 32 were cilostazol treated and 31 were the non-cilostazol-treated group. Outcome measures were binary restenosis by angiogram, reocclusion, target lesion revascularization (TLR), limb salvage rate and complete wound healing at 3 months. RESULT: Procedural success was obtained in all patients. The backgrounds and lesion characteristics of patients with isolated tibial artery disease and CLI did not differ significantly between the two groups. In a lesion-based analysis, binary restenosis and reocclusion were significantly lower in the cilostazol group than in the non-cilostazol group (56.8% vs. 86.0%; p = 0.015, 20.5% vs. 43.6%; p = 0.015, respectively). The TLR was also significantly lower in the cilostazol group (27.5% vs. 52.8%, p = 0.014). After adjustment for covariables, cilostazol was found to be associated with reduced angiographic restenosis, reocclusion and TLR rates in CLI patients at 3 months after infrapopliteal angioplasty. However, it remained unclear whether cilostazol was also associated with improved clinical outcomes. CONCLUSION:Cilostazol may be associated with reduced restenosis, reocclusion and clinically driven TLR at 3 months after infrapopliteal angioplasty.
Authors: Brandon Olivieri; Timothy E Yates; Sofia Vianna; Omosalewa Adenikinju; Robert E Beasley; Jon Houseworth Journal: Semin Intervent Radiol Date: 2019-02-05 Impact factor: 1.513
Authors: Courtney J Warner; Spencer W Greaves; Robin J Larson; David H Stone; Richard J Powell; Daniel B Walsh; Philip P Goodney Journal: J Vasc Surg Date: 2014-01-24 Impact factor: 4.268